Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy
- 31 July 2006
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 131 (1), 59-68
- https://doi.org/10.1053/j.gastro.2006.04.015
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Truly de novo Hepatitis B After Liver TransplantationAmerican Journal Of Gastroenterology, 2004
- Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantationLiver Transplantation, 2001
- De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor populationLiver Transplantation, 2001
- Severe clinical course of de novo hepatitis B infection after liver transplantationLiver Transplantation and Surgery, 1999
- INFECTIVITY OF HEPATIC ALLOGRAFTS WITH ANTIBODIES TO HEPATITIS B VIRUSTransplantation, 1997
- Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation DatabaseGastroenterology, 1997
- De novo and apparent de novo hepatitis B virus infection after liver transplantationJournal of Hepatology, 1997
- The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipientLiver Transplantation and Surgery, 1997
- The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ DonorsTransplantation, 1995
- "Occult" hepatitis B virus as source of infection in liver transplant recipientsThe Lancet, 1994